CytoAgents Archives - intelligence360

CytoAgents Receives Fourth Grant From National Institutes of Health to Advance Research on Cytokine Release Syndrome

October 16, 2025 Craig Etkin

PITTSBURGH–(BUSINESS WIRE)–CytoAgents, Inc., a clinical-stage biotechnology company developing a safe and effective preventative treatment for cytokine release syndrome (CRS) and the neurotoxicity immune effector cell-associated neurotoxicity syndrome (ICANS), announced today that it has been awarded…

CytoAgents has filed a notice of an exempt offering of securities to raise $15,204,008.00 in New Equity Investment.

May 23, 2023 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, CytoAgents is raising $15,204,008.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Teresa Whalen played a key role in…

Pittsburgh Pennsylvania based CytoAgents is raising $6,500,000.00 in New Equity Investment.

September 1, 2021 Craig Etkin

Pittsburgh, PA – According to filings with the U.S. Securities and Exchange Commission, CytoAgents is raising $6,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Teresa Whalen played a key…

intelligence360

The Intelligent News Source

Tag: CytoAgents